Di Yu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6528308/publications.pdf

Version: 2024-02-01

39	1,058	394421	434195
papers	citations	19 h-index	31 g-index

41	41	41	1621
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Anemoside B4 inhibits enterovirus 71 propagation in mice through upregulating 14-3-3 expression and type I interferon responses. Acta Pharmacologica Sinica, 2022, 43, 977-991.	6.1	13
2	CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nature Biomedical Engineering, 2022, 6, 830-841.	22.5	25
3	A qPCR-Based Method for Quantification of RCA Contaminants in Oncolytic Adenovirus Products. Frontiers in Molecular Biosciences, 2022, 9, .	3.5	2
4	A qPCR-Based Method for Quantification of Replication Competent Adenovirus (RCA) in Conditionally Replicating Oncolytic Adenoviruses. Methods in Molecular Biology, 2022, , 249-258.	0.9	1
5	Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-tumor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response. OncoImmunology, 2022, 11, .	4.6	5
6	In Situ Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy. Nano Letters, 2021, 21, 2224-2231.	9.1	116
7	IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma. Molecular Therapy - Oncolytics, 2021, 21, 37-46.	4.4	14
8	Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus. Molecular Therapy - Oncolytics, 2021, 21, 356-366.	4.4	7
9	Separable Microneedle Patch to Protect and Deliver DNA Nanovaccines Against COVID-19. ACS Nano, 2021, 15, 14347-14359.	14.6	73
10	Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death and Disease, 2020, 11, 48.	6.3	103
11	Abstract B110: Proinflammatory allogeneic dendritic cells promote activation of bystander immune cells and indirectly license antigen-specific T-cells. , 2019, , .		0
12	Abstract B175: Semliki Forest virus-mediated oncolytic immunotherapy in mouse GL261 glioblastoma model. , 2019, , .		0
13	Abstract A041: Hypoxia-responsive CAR T-cells. , 2019, , .		1
14	Multiple nuclear-replicating viruses require the stress-induced protein ZC3H11A for efficient growth. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3808-E3816.	7.1	35
15	Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models. OncoImmunology, 2018, 7, e1397250.	4.6	19
16	Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses. OncoImmunology, 2018, 7, e1395126.	4.6	24
17	Antischistosomal Properties of Hederacolchiside A1 Isolated from Pulsatilla chinensis. Molecules, 2018, 23, 1431.	3.8	20
18	CD93 promotes Î²1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis. Journal of Clinical Investigation, 2018, 128, 3280-3297.	8.2	100

#	Article	IF	Citations
19	Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and In Vivo Tumor Growth. Molecular Cancer Therapeutics, 2017, 16, 1705-1716.	4.1	32
20	Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity. Molecular Therapy - Oncolytics, 2017, 7, 67-75.	4.4	6
21	Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer. Neuroendocrinology, 2017, 105, 54-66.	2.5	24
22	Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus. Clinical Cancer Research, 2017, 23, 1519-1530.	7.0	43
23	Safe engineering of <scp>CAR</scp> T cells for adoptive cell therapy of cancer using longâ€term episomal geneÂtransfer. EMBO Molecular Medicine, 2016, 8, 702-711.	6.9	56
24	Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors. Immunotherapy, 2016, 8, 1355-1361.	2.0	15
25	HAdV-2-suppressed growth of SV40 T antigen-transformed mouse mammary epithelial cell-induced tumours in SCID mice. Virology, 2016, 489, 44-50.	2.4	0
26	Abstract A171: Long-term episomal gene transfer for safe engineering of T cells for adoptive cell therapy of cancer. , 2016, , .		0
27	Abstract A172: Allogeneic dendritic cells (AlloDCs) transduced with an infection-enhanced adenovirus as adjuvant for cancer immunotherapy. , 2016, , .		0
28	Abstract 2311: Adenovirus-transduced allogeneic dendritic cells for cancer immunotherapy. , 2016, , .		0
29	Chondroitin Sulfateâ€Coated DNAâ€Nanoplexes Enhance Transfection Efficiency by Controlling Plasmid Release from Endosomes: A New Insight into Modulating Nonviral Gene Transfection. Advanced Functional Materials, 2015, 25, 3907-3915.	14.9	43
30	Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. Science Signaling, 2015, 8, ra125.	3.6	52
31	A Hexon and Fiber-modified Adenovirus Expressing CD40L Improves the Antigen Presentation Capacity of Dendritic Cells. Journal of Immunotherapy, 2014, 37, 155-162.	2.4	3
32	Vector-EncodedHelicobacter pyloriNeutrophil-Activating Protein Promotes Maturation of Dendritic Cells with Th1 Polarization and Improved Migration. Journal of Immunology, 2014, 193, 2287-2296.	0.8	32
33	Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14001.	4.1	27
34	Tat-PTD-Modified Oncolytic Adenovirus Driven by the SCG3 Promoter and ASH1 Enhancer for Neuroblastoma Therapy. Human Gene Therapy, 2013, 24, 766-775.	2.7	8
35	An Infection-enhanced Oncolytic Adenovirus Secreting H. pylori Neutrophil-activating Protein with Therapeutic Effects on Neuroendocrine Tumors. Molecular Therapy, 2013, 21, 2008-2018.	8.2	29
36	Adenovirus Serotype 5 Vectors with Tat-PTD Modified Hexon and Serotype 35 Fiber Show Greatly Enhanced Transduction Capacity of Primary Cell Cultures. PLoS ONE, 2013, 8, e54952.	2.5	25

#	Article	IF	Citations
37	Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells. Gene Therapy, 2011, 18, 1052-1062.	4.5	27
38	Adenovirus with Hexon Tat-Protein Transduction Domain Modification Exhibits Increased Therapeutic Effect in Experimental Neuroblastoma and Neuroendocrine Tumors. Journal of Virology, 2011, 85, 13114-13123.	3.4	34
39	Double-Detargeted Oncolytic Adenovirus Shows Replication Arrest in Liver Cells and Retains Neuroendocrine Cell Killing Ability. PLoS ONE, 2010, 5, e8916.	2.5	43